Annual CFF
$6.89 M
-$15.29 M-68.95%
December 31, 2023
Summary
- As of February 8, 2025, AGRX annual cash flow from financing activities is $6.89 million, with the most recent change of -$15.29 million (-68.95%) on December 31, 2023.
- During the last 3 years, AGRX annual CFF has fallen by -$61.10 million (-89.87%).
Performance
AGRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly CFF
$0.00
-$2.54 M-100.00%
June 1, 2024
Summary
- As of February 8, 2025, AGRX quarterly cash flow from financing activities is $0.00, with the most recent change of -$2.54 million (-100.00%) on June 1, 2024.
- Over the past year, AGRX quarterly CFF has stayed the same.
Performance
AGRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM CFF
$1.77 M
-$6.88 M-79.53%
June 1, 2024
Summary
- As of February 8, 2025, AGRX TTM cash flow from financing activities is $1.77 million, with the most recent change of -$6.88 million (-79.53%) on June 1, 2024.
- Over the past year, AGRX TTM CFF has stayed the same.
Performance
AGRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
AGRX Cash From Financing Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -69.0% | 0.0% | 0.0% |
| 3 y3 years | -89.9% | 0.0% | 0.0% |
| 5 y5 years | +163.3% | 0.0% | 0.0% |
AGRX Cash From Financing Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -77.4% | at low | -100.0% | <-9999.0% | -95.8% | at low |
| 5 y | 5-year | -89.9% | at low | -100.0% | <-9999.0% | -98.3% | -44.9% |
| alltime | all time | -89.9% | -258.1% | -100.0% | <-9999.0% | -98.3% | -715.1% |
Agile Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2024 | - | $0.00(-100.0%) | $1.77 M(-79.5%) |
| Mar 2024 | - | $2.54 M(-620.5%) | $8.64 M(+25.5%) |
| Dec 2023 | $6.89 M(-68.9%) | -$487.00 K(+75.2%) | $6.89 M(-14.3%) |
| Sep 2023 | - | -$278.00 K(-104.0%) | $8.04 M(-55.7%) |
| Jun 2023 | - | $6.88 M(+783.7%) | $18.13 M(-22.8%) |
| Mar 2023 | - | $778.00 K(+17.9%) | $23.48 M(+5.9%) |
| Dec 2022 | $22.18 M(-27.1%) | $660.00 K(-93.3%) | $22.18 M(-47.9%) |
| Sep 2022 | - | $9.82 M(-19.7%) | $42.60 M(+21.6%) |
| Jun 2022 | - | $12.22 M(-2437.5%) | $35.05 M(+19.1%) |
| Mar 2022 | - | -$523.00 K(-102.5%) | $29.41 M(-3.3%) |
| Dec 2021 | $30.42 M(-55.3%) | $21.08 M(+832.0%) | $30.42 M(+214.7%) |
| Sep 2021 | - | $2.26 M(-65.7%) | $9.67 M(+30.6%) |
| Jun 2021 | - | $6.59 M(+1262.6%) | $7.40 M(+659.4%) |
| Mar 2021 | - | $484.00 K(+48.9%) | $975.00 K(-98.6%) |
| Dec 2020 | $67.98 M(+60.3%) | $325.00 K(>+9900.0%) | $67.98 M(-22.0%) |
| Sep 2020 | - | $0.00(-100.0%) | $87.11 M(-12.9%) |
| Jun 2020 | - | $166.00 K(-99.8%) | $100.00 M(-1.2%) |
| Mar 2020 | - | $67.49 M(+247.1%) | $101.24 M(+138.7%) |
| Dec 2019 | $42.41 M(-489.6%) | $19.45 M(+50.8%) | $42.41 M(+149.1%) |
| Sep 2019 | - | $12.89 M(+818.4%) | $17.03 M(+595.3%) |
| Jun 2019 | - | $1.40 M(-83.8%) | $2.45 M(-506.8%) |
| Mar 2019 | - | $8.67 M(-246.0%) | -$602.00 K(-94.5%) |
| Dec 2018 | -$10.89 M | -$5.94 M(+252.3%) | -$10.89 M(+68.8%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$1.69 M(+2.4%) | -$6.45 M(-152.6%) |
| Jun 2018 | - | -$1.65 M(+1.9%) | $12.26 M(-1.6%) |
| Mar 2018 | - | -$1.62 M(+7.6%) | $12.45 M(-4.8%) |
| Dec 2017 | $13.07 M(-65.3%) | -$1.50 M(-108.8%) | $13.07 M(-10.3%) |
| Sep 2017 | - | $17.02 M(-1273.8%) | $14.58 M(-660.2%) |
| Jun 2017 | - | -$1.45 M(+46.0%) | -$2.60 M(+126.9%) |
| Mar 2017 | - | -$993.00 K(<-9900.0%) | -$1.15 M(-103.0%) |
| Dec 2016 | $37.69 M(+88.6%) | $6000.00(-103.6%) | $37.69 M(-0.1%) |
| Sep 2016 | - | -$166.00 K(-2866.7%) | $37.74 M(-1.0%) |
| Jun 2016 | - | $6000.00(-100.0%) | $38.13 M(-0.4%) |
| Mar 2016 | - | $37.84 M(>+9900.0%) | $38.30 M(+91.7%) |
| Dec 2015 | $19.98 M(-62.1%) | $61.00 K(-73.1%) | $19.98 M(-0.0%) |
| Sep 2015 | - | $227.00 K(+29.7%) | $19.99 M(+1.1%) |
| Jun 2015 | - | $175.00 K(-99.1%) | $19.76 M(-72.6%) |
| Mar 2015 | - | $19.52 M(>+9900.0%) | $72.22 M(+37.1%) |
| Dec 2014 | $52.66 M(>+9900.0%) | $67.40 K(>+9900.0%) | $52.66 M(-0.0%) |
| Sep 2014 | - | $0.00(-100.0%) | $52.66 M(0.0%) |
| Jun 2014 | - | $52.63 M(<-9900.0%) | $52.66 M(>+9900.0%) |
| Mar 2014 | - | -$40.20 K(-157.4%) | $29.80 K(-57.4%) |
| Dec 2013 | $70.00 K(-99.8%) | $70.00 K(>+9900.0%) | $70.00 K(>+9900.0%) |
| Sep 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Jun 2013 | - | $0.00(0.0%) | $0.00(0.0%) |
| Mar 2013 | - | $0.00 | $0.00 |
| Dec 2012 | $40.11 M | - | - |
FAQ
- What is Agile Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Agile Therapeutics?
- What is Agile Therapeutics annual CFF year-on-year change?
- What is Agile Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Agile Therapeutics?
- What is Agile Therapeutics quarterly CFF year-on-year change?
- What is Agile Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Agile Therapeutics?
- What is Agile Therapeutics TTM CFF year-on-year change?
What is Agile Therapeutics annual cash flow from financing activities?
The current annual CFF of AGRX is $6.89 M
What is the all time high annual CFF for Agile Therapeutics?
Agile Therapeutics all-time high annual cash flow from financing activities is $67.98 M
What is Agile Therapeutics annual CFF year-on-year change?
Over the past year, AGRX annual cash flow from financing activities has changed by -$15.29 M (-68.95%)
What is Agile Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of AGRX is $0.00
What is the all time high quarterly CFF for Agile Therapeutics?
Agile Therapeutics all-time high quarterly cash flow from financing activities is $67.49 M
What is Agile Therapeutics quarterly CFF year-on-year change?
Over the past year, AGRX quarterly cash flow from financing activities has changed by $0.00 (0.00%)
What is Agile Therapeutics TTM cash flow from financing activities?
The current TTM CFF of AGRX is $1.77 M
What is the all time high TTM CFF for Agile Therapeutics?
Agile Therapeutics all-time high TTM cash flow from financing activities is $101.24 M
What is Agile Therapeutics TTM CFF year-on-year change?
Over the past year, AGRX TTM cash flow from financing activities has changed by $0.00 (0.00%)